Core Insights - The market performance of Clopidogrel exceeded expectations, becoming a "blockbuster" drug that significantly supported Sanofi's growth and provided a capital foundation for subsequent acquisitions [1] Group 1: Company Growth and Strategy - Sanofi's merger with Genzyme initiated resource integration and product line optimization to consolidate its industry position, avoiding risks associated with patent cliffs [2] - Following the merger, Sanofi's sales surged, surpassing €30 billion in 2010, making it the fourth-largest pharmaceutical company globally [2] - Sanofi invested $17 billion in acquisitions from 2008 to 2010, enhancing its over-the-counter and generic drug lines, thereby reducing reliance on single blockbuster drugs [2] Group 2: Diversification and Innovation - After 2010, Sanofi expanded into the orphan drug sector, acquiring Genzyme for $21 billion, which helped elevate its revenue and establish it as a leader in orphan drugs [3] - Sanofi's total sales grew from €30.4 billion in 2010 to €34 billion in 2015, demonstrating resilience against the patent cliff of Clopidogrel [3] - The company underwent strategic adjustments post-2016, forming five key business segments and optimizing operations through asset swaps and acquisitions [4] Group 3: Long-term Growth and Future Prospects - Sanofi successfully navigated patent cliff crises, maintaining low debt levels while introducing new potential products like U300 insulin and Dupixent [4] - The company is actively exploring emerging fields such as RNAi and tumor immunotherapy to ensure long-term growth [4] - Sanofi's development history illustrates the importance of innovation and adaptability in a competitive market environment [5][6]